New CDSCO import registration certificate obtained for FoliColor oxidative hair colour
Amwill Health Care has obtained a new CDSCO import registration certificate (RC/COS-007631) for FoliColor oxidative hair colour, variant Black.
- Registration Certificate No.
- RC/COS-007631
- Validity
- 08-Oct-2026 to 07-Oct-2031
- Product and Variant
- FoliColor oxidative hair colour, variant Black
What the update says
Amwill Health Care has informed BSE that it has obtained a new licence/regulatory approval for the import of FoliColor oxidative hair colour products into India. The licence is a new grant from the Central Drugs Standard Control Organization (CDSCO).
Key details
- Authority: Central Drugs Standard Control Organization (CDSCO)
- Type: Import registration certificate for import of cosmetics into India, Registration Certificate No. RC/COS-007631
- Product: FoliColor hair colour; variant Black
- Date of grant and receipt by the company: October 09, 2026
- Validity: in force from 08-Oct-2026 up to 07-Oct-2031, unless sooner suspended or cancelled
- New grant, not a renewal or amendment
- The supplier is not a related party
What the company says it means
In simple terms, the company can now bring this hair colour product into India and sell it commercially. The update states that the licence enables the company to commence import and commercial sale of the product in India, and that it is expected to expand the company's product portfolio and revenue. The update describes the benefit in terms of what the licence permits the company to do.
Other points from the update
- Withdrawal, cancellation or suspension of the licence is marked as Not Applicable.
- The follow-up intimation of actual impact and corrective action on any withdrawal, cancellation or suspension is also marked as Not Applicable.
- The information is also being made available on the company's website.
How to read this
A licence to import and commercially sell a product is a business development for the company, since it adds a product that can be sold in the Indian market. The company links the approval to a wider product portfolio and to revenue, and readers would track the company's later updates for the actual commercial outcome.
Also from Amwill Health Care
Investment Committee approves up to Rs. 3 crore across two SEBI-registered AIF schemes
25 Sep 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.